On August 5, 2026, shareholders of 60 Degrees Pharmaceuticals, Inc. approved a reverse stock split with a ratio ranging from 1-for-5 to 1-for-10, as determined by the Board in its sole discretion. The company also increased shares available under its 2022 Equity Incentive Plan by 800,000 and ratified RBSM LLP as auditor. Additionally, shareholders approved a management success fee of 5% to 6% of deal proceeds for transactions involving Arakoda. All five directors were re-elected with majority support. The company operates in the pharmaceutical industry.

60 Degrees Pharmaceuticals, Inc. prepared a statistical analysis plan for an interim analysis of its tafenoquine trial for severe babesiosis (NCT0627370). The interim analysis will occur on 10/30/26 or after 24 of 33 patients are randomized and followed for 50 days, with potential for early reporting if conditional power is at least 80%. The company intends to apply for a Commissioner's National Priority Review Voucher if trial results support a supplementary New Drug Application (sNDA) submission by Q1 2028. 60 Degrees Pharmaceuticals, Inc. is a pharmaceutical company developing drug candidates for infectious diseases.